Promoting Competition in Drug Pricing: A Review of Recent Congressional Legislation.
Drug Prices
Generic Drug
Hopping
Patents
Product
Journal
The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics
ISSN: 1748-720X
Titre abrégé: J Law Med Ethics
Pays: England
ID NLM: 9315583
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
10
1
2022
pubmed:
11
1
2022
medline:
27
1
2022
Statut:
ppublish
Résumé
Brand-name prescription drug manufacturers use various strategies to extend their market exclusivity periods by delaying generic or biosimilar competition. Recent Congressional legislation has targeted four such tactics. We analyze these proposals and assess their likely effect on competition in the U.S. drug market.
Identifiants
pubmed: 35006061
doi: 10.1017/jme.2021.93
pii: S1073110521000930
doi:
Substances chimiques
Biosimilar Pharmaceuticals
0
Drugs, Generic
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng